The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging targeted therapy combination strategies in genitourinary malignancies
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Emerging immunotherapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Diversity in HER2 Expression Among Gynecologic Cancers
Diversity in HER2 Expression Among Gynecologic Cancers
